耳鼻咽喉科・頭頸部外科95巻4号

2023年04月発行

特集 睡眠時無呼吸症候群の診療エッセンシャル 《各種治療の適応とその効果》

薬物治療／体位変換治療

著者： 西村洋一¹² 鈴木雅明¹

所属機関： ¹帝京大学ちば総合医療センター耳鼻咽喉科 ^{2 3}

ページ範囲：P.312 - P.320

POINT

●閉塞性睡眠時無呼吸（OSA）の発症は多因子由来であるゆえに単一治療法での根治治療が困難であり，エンドタイプ，フィノタイプに沿った「個別化治療」が必要である。

●治療オプション（選択肢）の1つに「体位変換治療」がある。

●新たな治療オプションである「薬物治療」に期待が高まる。

●「薬物治療」は解剖を補正しない。すなわち「手術治療」は不滅である。

●治療薬にも持続気道陽圧（CPAP）と同様に継続率，合併症を含めた「アクセプタンス」の課題がある。

●治療薬の開発は「時間」「予算」「リサーチマインド」が必要である。

参考文献

1）Fleury Curado T, et al：Chemogenetic stimulation of the hypoglossal neurons improves upper airway patency. Sci Rep 7：44392, 2017

2）Fleury Curado T, et al：Designer receptors exclusively activated by designer drugs approach to treatment of sleep-disordered breathing. Am J Respir Crit Care Med 203：102-110, 2021

3）Fleury Curado T, et al：Silencing of hypoglossal motoneurons leads to sleep disordered breathing in lean mice. Front Neurol 9：962, 2018

4）Nishimura Y, et al：A novel non-invasive approach for measuring upper airway collapsibility in mice. Front Neurol 9：985, 2018

5）Suzuki M：Obstructive sleep apnea：consideration of its pathogenesis. Auris Nasus Larynx 49：313-321, 2022

6）Lee MC, et al：Establishment of a rabbit model of obstructive sleep apnea by paralyzing the genioglossus. JAMA Otolaryngol Head Neck Surg 139：834-840, 2013

7）Sood S, et al：Genioglossus muscle activity and serotonergic modulation of hypoglossal motor output in obese Zucker rats. J Appl Physiol（1985） 102：2240-2250, 2007

8）Chan E, et al：Endogenous excitatory drive modulating respiratory muscle activity across sleep-wake states. Am J Respir Crit Care Med 174：1264-1273, 2006

9）Song G, et al：α2-Adrenergic blockade rescues hypoglossal motor defense against obstructive sleep apnea. JCI Insight 2：e91456, 2017

10）Kubin L, et al：Control of upper airway motoneurons during REM sleep. News Physiol Sci 13：91-97, 1998

11）Grace KP, et al：Identification of the mechanism mediating genioglossus muscle suppression in REM sleep. Am J Respir Crit Care Med 187：311-319, 2013

channel modulation causes genioglossus inhibition in REM sleep and is a strategy for reactivation. Respir Physiol Neurobiol 188：277-288, 2013

13）Taranto-Montemurro L, et al：Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. Eur Respir J 48：1340-1350, 2016

14）Taranto-Montemurro L, et al：The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial. Am J Respir Crit Care Med 199：1267-1276, 2019

15）Aishah A, et al：Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity. J Appl Physiol（1985） 130：1373-1382, 2021

16）Chen TY, et al：Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea. Sci Rep 11：12526, 2021

17）Kim LJ, et al：The role of animal models in developing pharmacotherapy for obstructive sleep apnea. J Clin Med 8：2049, 2019

18）Perger E, et al：Reboxetine plus oxybutynin for OSA treatment：a 1-week, randomized, placebo-controlled, double-blind crossover trial. Chest 161：237-247, 2022

19）Rosenberg R, et al：Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA. J Clin Sleep Med 18：2837-2844, 2022

20）Taranto-Montemurro L, et al：Effects of the combination of atomoxetine and oxybutynin on OSA endotypic traits. Chest 157：1626-1636, 2020

21）Kinouchi T, et al：Effects of the combination of atomoxetine and oxybutynin in Japanese patients with obstructive sleep apnoea：a randomized controlled crossover trial. Respirology, 2022〔Online ahead of print〕

22）Park E, et al：Systemic vs. central administration of common hypnotics reveals opposing effects on genioglossus muscle activity in rats. Sleep 31：355-365, 2008

23）Eckert DJ, et al：Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci（Lond） 120：505-514, 2011

24）Wang T, et al：Increased carbonic anhydrase activity is associated with sleep apnea severity and related hypoxemia. Sleep 38：1067-1073, 2015

25）Morris DL, et al：Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 297：E1247-E1259, 2009

26）Breslow MJ, et al：Effect of leptin deficiency on metabolic rate in ob/ob mice. Am J Physiol 276：E443-E449, 1999

27）Peng Y, et al：Chronic intermittent hypoxia enhances carotid body chemoreceptor response to low oxygen. Adv Exp Med Biol 499：33-38, 2001

28）O'donnell CP, et al：Leptin prevents respiratory depression in obesity. Am J Respir Crit Care Med 159：1477-1484, 1999

29）Caballero-Eraso C, et al：Leptin acts in the carotid bodies to increase minute ventilation during wakefulness and sleep and augment the hypoxic ventilatory response. J Physiol 597：151-172, 2019

30）Fleury Curado T, et al：Sleep-disordered breathing in C57BL/6J mice with diet-induced obesity. Sleep 41：zsy089, 2018

31）Pho H, et al：The effect of leptin replacement on sleep-disordered breathing in the leptin-deficient ob/ob mouse. J Appl Physiol（1985） 120：78-86, 2016

32）Berger S, et al：Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity. Am J Respir Crit Care Med 199：773-783, 2019

33）Peng YJ, et al：Complementary roles of gasotransmitters CO and H2S in sleep apnea. Proc Natl Acad Sci U S A 114：1413-1418, 2017

34）Nishimura Y, et al：Simplified upper airway collapsibility measurement for uvulopalatopharyngoplasty（UPPP）：Perspectives. Otorhinolaryngol Hypersensitivity Treat 1：1-2, 2020

35）Saigusa H, et al：Three-dimensional morphological analyses of positional dependence in patients with obstructive sleep apnea syndrome. Anesthesiology 110：885-890, 2009

36）Suzuki M, et al：Effect of position therapy and oral devices on sleep parameters in patients with obstructive sleep apnea. Eur Arch Otorhinolaryngol 278：4545-4550, 2021